



Amendments to the Claims


1. (Original) A compound having a structural Formula I,



and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof,  
wherein:



E is: O, S or NR<sup>14</sup>;

W is:  , hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, (CH<sub>2</sub>)<sub>n</sub>-C<sub>3</sub>-C<sub>6</sub> cycloalkyl, haloalkyl or acyl;

Q is: -C(O)OR<sup>6</sup> or R<sup>6A</sup>;

X is: a bond, C, O, S or S[O]<sub>p</sub>;

Y is: a bond, S, C or O;

- Z is: a) aliphatic group,  
b) aryl,  
c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,  
d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,

e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and

f) heterocyclyl;

wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

m and n' are each independently: 0, 1, 2, 3 or 4;

n is: 0, 1, 2 or 3;

p is: 1 or 2;

r is: 1, 2, 3 or 4;

v is: 1 or 2;

R<sup>1</sup> is: hydrogen, wherein when Z is phenyl or naphthyl and R<sup>2</sup> is H, R<sup>1</sup> is not H,

haloalkyl,

C<sub>1</sub>-C<sub>6</sub> alkyl,

C<sub>1</sub>-C<sub>6</sub> alkyl-C<sub>1</sub>-C<sub>6</sub> alkoxy,

C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,

C<sub>2</sub>-C<sub>6</sub> alkenyl,

C<sub>2</sub>-C<sub>6</sub> alkynyl,

(CH<sub>2</sub>)<sub>n</sub> C<sub>3</sub>-C<sub>6</sub> cycloalkyl,

C<sub>1</sub>-C<sub>6</sub> alkoxy,

aryl, or

R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and

wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

R<sup>1a</sup> and R<sup>1b</sup> are each independently:

hydrogen,

C<sub>1</sub>-C<sub>6</sub> alkyl, or

R<sup>1</sup> and R<sup>1a</sup>, R<sup>1</sup> and R<sup>1b</sup>, R<sup>2</sup> and R<sup>1a</sup>, R<sup>2</sup> and R<sup>1b</sup> or R<sup>1a</sup> and R<sup>1b</sup> together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R<sup>1a</sup> and R<sup>1b</sup> is not hydrogen;

R<sup>2</sup> is: hydrogen,  
haloalkyl,  
C<sub>1</sub>-C<sub>6</sub> alkyl,  
C<sub>1</sub>-C<sub>6</sub> alkyl-C<sub>1</sub>-C<sub>6</sub> alkoxy,  
C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,  
C<sub>2</sub>-C<sub>6</sub> alkenyl,  
C<sub>2</sub>-C<sub>6</sub> alkynyl,  
(CH<sub>2</sub>)<sub>n</sub> C<sub>3</sub>-C<sub>6</sub> cycloalkyl,  
C<sub>1</sub>-C<sub>6</sub> alkoxy,  
aryl, or  
R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclcyl ring, and  
wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted  
with one or more groups independently selected from R<sup>15</sup>;

R<sup>2a</sup> is: hydrogen, halo or C<sub>1</sub>-C<sub>6</sub> alkyl and wherein R<sup>2</sup> and R<sup>2a</sup> together being a 3- to 8-membered  
ring; and wherein alkyl being optionally substituted with one or more groups  
independently selected from R<sup>15</sup>;

R<sup>3</sup> is: hydrogen,  
halo,  
cyano,  
haloalkyl,  
C<sub>1</sub>-C<sub>6</sub> alkyl,  
(CH<sub>2</sub>)<sub>n</sub> C<sub>3</sub>-C<sub>6</sub> cycloalkyl,  
(C<sub>1</sub>-C<sub>4</sub> alkyl)-heterocyclcyl, wherein the heterocyclcyl being optionally substituted with  
oxo,  
(C<sub>1</sub>-C<sub>4</sub> alkyl)-NR<sup>7</sup>C(O)<sub>p</sub>R<sup>9</sup>, and  
wherein alkyl, cycloalkyl and heterocyclcyl being optionally substituted with one or more  
groups independently selected from R<sup>15</sup>;

R<sup>4</sup> and R<sup>5</sup> are each independently:  
hydrogen,  
halo,

C<sub>1</sub>-C<sub>6</sub> alkyl  
C<sub>1</sub>-C<sub>6</sub> alkoxy;  
aryloxy;  
N(R<sup>8</sup>)<sub>2</sub>,  
SR<sup>8</sup> or  
R<sup>4</sup> and R<sup>5</sup> together being a 3- to 8-membered ring;

R<sup>6</sup> is: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or aminoalkyl;

R<sup>6A</sup> is: carboxamide, C<sub>1</sub>-C<sub>3</sub> alkynitrile, sulfonamide, acylsulfonamide or tetrazole;

R<sup>7</sup> is: hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>8</sup> and R<sup>9</sup> are each independently:

hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, heteroaryl, or heterocyclyl, and  
wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more  
substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo,  
haloalkyl, haloalkyloxy, aryloxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy;

R<sup>14</sup> is: hydrogen, aryl, C<sub>1</sub>-C<sub>6</sub> alkyl, or C<sub>1</sub>-C<sub>6</sub> alkyl-COOR<sup>6</sup>, and  
wherein aryl and alkyl being optionally substituted with one or more groups independently  
selected from R<sup>15</sup>; and

R<sup>15</sup> is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl,  
C<sub>1</sub>-C<sub>6</sub> alkoxy, (CH<sub>2</sub>)<sub>n</sub>-C<sub>3</sub>-C<sub>6</sub> cycloalkyl, N(R<sup>8</sup>)<sub>2</sub>, NR<sup>8</sup>S(O)<sub>2</sub>R<sup>9</sup>, NR<sup>8</sup>C(O)<sub>p</sub>R<sup>9</sup>, C(O)NR<sup>8</sup>R<sup>9</sup>,  
C(O)<sub>p</sub>R<sup>8</sup>, SR<sup>8</sup>, S(O)<sub>p</sub>R<sup>8</sup> or S(O)<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>.

2. (Original) The compound Claim 1, wherein X and Y are respectively S and O; S and C; or C and O.


3. (Original) The compound of Claim 2, wherein Z is C<sub>1</sub>-C<sub>6</sub> alkyl, aryl or heteroaryl.

4. (Original) The compound of Claim 3, wherein Z is phenyl, naphthyl, thiophenyl, oxazolyl, isooxazolyl, pyridyl, benzothiophenyl, benzofuranyl, indolyl, isoindolyl, pyrazolyl, imidazolyl, 1,4 benzodioxan, benzooxazolyl, benzothiazolyl, benzoimidazolyl, or 2,3-dihydrobenzofuranyl.

5. (Original) The compound of Claim 4, wherein R<sup>1</sup> is C<sub>3</sub>-C<sub>6</sub> alkyl or (CH<sub>2</sub>)<sub>n</sub>-C<sub>3</sub>-C<sub>6</sub> cycloalkyl; R<sup>2</sup> and R<sup>3</sup> are each independently C<sub>1</sub>-C<sub>3</sub> alkyl; and r is 1.

6. (Original) The compound Claim 5, wherein X is positioned para to Y; and R<sup>3</sup> is positioned ortho to Y.

7. (Original) A compound having a structural Formula II,



and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

Q is: -C(O)OR<sup>6</sup> or R<sup>6A</sup>;

X is: a bond, C, O, S or S[O]<sub>p</sub>;

Y is: a bond, S, C or O;

Z is: a) aliphatic group,  
b) aryl,  
c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,  
d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,

e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and

f) heterocyclyl;

wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

m and n' are each independently: 0, 1, 2, 3 or 4;

n is: 0, 1, 2 or 3;

p is: 1 or 2;

r is: 1, 2, 3 or 4;

R<sup>1</sup> is: aryl,

haloalkyl,

C<sub>1</sub>-C<sub>6</sub> alkyl,

C<sub>1</sub>-C<sub>6</sub> alkyl-C<sub>1</sub>-C<sub>6</sub> alkoxy,

C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,

C<sub>2</sub>-C<sub>6</sub> alkenyl,

C<sub>2</sub>-C<sub>6</sub> alkynyl,

(CH<sub>2</sub>)<sub>n</sub>-C<sub>3</sub>-C<sub>6</sub> cycloalkyl,

C<sub>1</sub>-C<sub>6</sub> alkoxy or

R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and

wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

R<sup>1a</sup> and R<sup>1b</sup> are each independently:

hydrogen,

C<sub>1</sub>-C<sub>6</sub> alkyl, or

R<sup>1</sup> and R<sup>1a</sup>, R<sup>1</sup> and R<sup>1b</sup>, R<sup>2</sup> and R<sup>1a</sup>, R<sup>2</sup> and R<sup>1b</sup> or R<sup>1a</sup> and R<sup>1b</sup> together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R<sup>1a</sup> and R<sup>1b</sup> is not hydrogen;

R<sup>2</sup> is: hydrogen,

haloalkyl,

C<sub>1</sub>-C<sub>6</sub> alkyl,  
C<sub>1</sub>-C<sub>6</sub> alkyl-C<sub>1</sub>-C<sub>6</sub> alkoxy,  
C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,  
C<sub>2</sub>-C<sub>6</sub> alkenyl,  
C<sub>2</sub>-C<sub>6</sub> alkynyl,  
(CH<sub>2</sub>)<sub>n</sub> C<sub>3</sub>-C<sub>6</sub> cycloalkyl,  
C<sub>1</sub>-C<sub>6</sub> alkoxy,  
aryl, or  
R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and  
wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted  
with one or more groups independently selected from R<sup>15</sup>;

R<sup>2a</sup> is: hydrogen, halo or C<sub>1</sub>-C<sub>6</sub> alkyl and wherein R<sup>2</sup> and R<sup>2a</sup> together being a 3- to 8-membered  
ring; and wherein alkyl being optionally substituted with one or more groups  
independently selected from R<sup>15</sup>;

R<sup>3</sup> is: hydrogen,  
halo,  
cyano,  
haloalkyl,  
C<sub>1</sub>-C<sub>6</sub> alkyl,  
(CH<sub>2</sub>)<sub>n</sub> C<sub>3</sub>-C<sub>6</sub> cycloalkyl,  
(C<sub>1</sub>-C<sub>4</sub> alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted with  
oxo,  
(C<sub>1</sub>-C<sub>4</sub> alkyl)-NR<sup>7</sup>C(O)<sub>p</sub>R<sup>9</sup>, and  
wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more  
groups independently selected from R<sup>15</sup>;

R<sup>4</sup> and R<sup>5</sup> are each independently:

hydrogen,  
halo,  
C<sub>1</sub>-C<sub>6</sub> alkyl  
C<sub>1</sub>-C<sub>6</sub> alkoxy;

aryloxy;

$N(R^8)_2$ ,

$SR^8$  or

$R^4$  and  $R^5$  together being a 3- to 8-membered ring;

$R^6$  is: hydrogen,  $C_1$ - $C_6$  alkyl or aminoalkyl;

$R^{6A}$  is: carboxamide,  $C_1$ - $C_3$  alkyl nitrile, sulfonamide, acylsulfonamide or tetrazole;

$R^7$  is: hydrogen or  $C_1$ - $C_6$  alkyl;

$R^8$  and  $R^9$  are each independently:

hydrogen,  $C_1$ - $C_6$  alkyl, aryl, heteroaryl, or heterocyclyl, and

wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo,  $C_1$ - $C_6$  alkyl and  $C_1$ - $C_6$  alkoxy;

$R^{15}$  is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $(CH_2)_n$ - $C_3$ - $C_6$  cycloalkyl,  $N(R^8)_2$ ,  $NR^8S(O)_2R^9$ ,  $NR^8C(O)_pR^9$ ,  $C(O)NR^8R^9$ ,  $C(O)_pR^8$ ,  $SR^8$ ,  $S(O)_pR^8$  or  $S(O)_2NR^8R^9$ .

8. (Original) The compound of Claim 7, wherein X and Y are respectively S and O; S and C; or C and O.

9. (Original) The compound of Claim 8, wherein Z is  $C_1$ - $C_6$  alkyl, aryl or heteroaryl.


10. (Original) The compound of Claim 9, wherein Z is phenyl, naphthyl, thiophenyl, oxazolyl, isooxazolyl, pyridyl, benzothiophenyl, benzofuranyl, indolyl, isoindolyl, pyrazolyl, imidazolyl, 1,4 benzodioxan, benzooxazolyl, benzothiazolyl, benzoimidazolyl, or 2,3-dihydrobenzofuranyl.

11. (Original) The compound of Claim 10, wherein  $R^1$  is  $C_3$ - $C_6$  alkyl or  $(CH_2)_n$ - $C_3$ - $C_6$  cycloalkyl;  $R^2$  and  $R^3$  are each independently  $C_1$ - $C_3$  alkyl; and r is 1.



12. (Original) The compound Claim 11, wherein X is positioned para to Y; and R<sup>3</sup> is positioned ortho to Y.

13. (Original) The compound of Claim 7, wherein the compound having a structural Formula III,



and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

n is: 1 or 2;

r is: 1, 2, 3, or 4;

X is: S or C;

Y is: C or O;


Z is: aryl or a 5- to 10-membered heteroaryl,

wherein aryl and heteroaryl being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

R<sup>1</sup> and R<sup>2</sup> are each independently: C<sub>1</sub>-C<sub>6</sub> alkyl or (CH<sub>2</sub>)<sub>n</sub>-C<sub>3</sub>-C<sub>6</sub> cycloalkyl; and

R<sup>1a</sup> and R<sup>1b</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are each independently: hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl.

14. (Original) The compound of Claim 13, wherein the compound having a structural Formula IV,



and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof,

wherein:

q is 1, 2, 3, 4, or 5;


$R^8$  and  $R^9$  are each independently:

hydrogen,  $C_1$ - $C_6$  alkyl, aryl, heteroaryl, or heterocyclyl,

wherein alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo,  $C_1$ - $C_6$  alkyl and  $C_1$ - $C_6$  alkoxy; and;

$R^{12}$  is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryl, heteroaryl, aryloxy, oxo,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $(CH_2)_n C_3$ - $C_6$  cycloalkyl,  $N(R^8)_2$ ,  $NR^8 S(O)_2 R^9$ ,  $NR^8 C(O)_p R^9$ ,  $C(O)NR^8 R^9$ ,  $C(O)_p R^8$ ,  $SR^8$ ,  $S(O)_p R^8$  or  $S(O)_2 NR^8 R^9$ .


15. (Original) The compound of Claim 14, wherein the compound having a structural Formula V,



and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein  $R^1$  and  $R^2$  are each independently  $C_1$ - $C_4$  alkyl or  $(CH_2)_n C_3$ - $C_6$  cycloalkyl;  $R^3$  is  $C_1$ - $C_4$  alkyl;  $(R^{12})_1$  is halo, haloalkyl, or haloalkyloxy; and  $(R^{12})_2$  is F, Cl or Br.

16. (Cancelled)

17. (Original) A compound having a structural Formula VI,



and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

X is: a bond, C, O, S or S[O]<sub>p</sub>;

Y is: a bond, S, C or O;

Z is: heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S, and wherein heteroaryl being optionally substituted with one or more groups selected from R<sup>15</sup>;

n is: 0, 1, 2 or 3;

n' is: 0, 1, 2, 3 or 4;

p is: 1 or 2;

r is: 1, 2, 3 or 4;

R<sup>1</sup> is: hydrogen,

haloalkyl,

C<sub>1</sub>-C<sub>6</sub> alkyl,

C<sub>1</sub>-C<sub>6</sub> alkyl-C<sub>1</sub>-C<sub>6</sub> alkoxy,

C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,

C<sub>2</sub>-C<sub>6</sub> alkenyl,

C<sub>2</sub>-C<sub>6</sub> alkynyl,

(CH<sub>2</sub>)<sub>n</sub>-C<sub>3</sub>-C<sub>6</sub> cycloalkyl,

C<sub>1</sub>-C<sub>6</sub> alkoxy,

aryl, or

R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclcyl ring, and

wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

R<sup>1a</sup> and R<sup>1b</sup> are each independently:

hydrogen,

C<sub>1</sub>-C<sub>6</sub> alkyl, or

$R^1$  and  $R^{1a}$ ,  $R^1$  and  $R^{1b}$ ,  $R^2$  and  $R^{1a}$ ,  $R^2$  and  $R^{1b}$  or  $R^{1a}$  and  $R^{1b}$  together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of  $R^{1a}$  and  $R^{1b}$  is not hydrogen;

$R^2$  is: hydrogen,  
haloalkyl,  
 $C_1$ - $C_6$  alkyl,  
 $C_1$ - $C_6$  alkyl- $C_1$ - $C_6$  alkoxy,  
 $C_1$ - $C_6$  alkyl-aryl,  
 $C_2$ - $C_6$  alkenyl,  
 $C_2$ - $C_6$  alkynyl,  
 $(CH_2)_n$ - $C_3$ - $C_6$  cycloalkyl,  
 $C_1$ - $C_6$  alkoxy,  
aryl, or  
 $R^1$  and  $R^2$  together being a 5- to 8-membered heterocyclyl ring, and  
wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from  $R^{15}$ ;

$R^{2a}$  is: hydrogen, halo or  $C_1$ - $C_6$  alkyl and wherein  $R^2$  and  $R^{2a}$  together being a 3- to 8-membered ring; and wherein alkyl being optionally substituted with one or more groups independently selected from  $R^{15}$ ;

$R^3$  is: hydrogen,  
halo,  
cyano,  
haloalkyl,  
 $C_1$ - $C_6$  alkyl,  
 $(CH_2)_n$ - $C_3$ - $C_6$  cycloalkyl,  
 $(C_1$ - $C_4$  alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted with oxo,  
 $(C_1$ - $C_4$  alkyl)- $NR^7C(O)_pR^9$ , and  
wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from  $R^{15}$ ;

$R^6$  is: hydrogen,  $C_1$ - $C_6$  alkyl or aminoalkyl;


$R^7$  is: hydrogen or  $C_1$ - $C_6$  alkyl;

$R^8$  and  $R^9$  are each independently:

hydrogen,  $C_1$ - $C_6$  alkyl, aryl, heteroaryl, or heterocyclyl, and  
wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more  
substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo,  
haloalkyl, haloalkyloxy, aryloxy, oxo,  $C_1$ - $C_6$  alkyl and  $C_1$ - $C_6$  alkoxy; and

$R^{15}$  is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo,  $C_1$ - $C_6$  alkyl,  
 $C_1$ - $C_6$  alkoxy,  $N(R^8)_2$ ,  $NR^8S(O)_2R^9$ ,  $NR^8C(O)_pR^9$ ,  $C(O)NR^8R^9$ ,  $C(O)_pR^8$ ,  $SR^8$ ,  $S(O)_pR^8$  or  
 $S(O)_2NR^8R^9$ .

18. (Original) The compound of Claim 17, wherein the compound having a  
structural Formula VII,



and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof,  
wherein:

q is: 1, 2, 3, or 4;


T is: O,  $NR^{1c}$  or S;

$R^{1c}$  is: hydrogen or  $C_1$ - $C_6$  alkyl;

$R^{10}$  and  $R^{11}$  are each independently:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy,  
 $C_1$ - $C_6$  alkyl or  $C_1$ - $C_6$  alkoxy; and  
wherein alkyl, aryloxy, and alkoxy being optionally substituted with one or more groups  
independently selected from  $R^{15}$ .

19. (Original) The compound of Claim 18, wherein the compound having a structural Formula VIII,



and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is: 1 or 2;

R<sup>1</sup> is: C<sub>3</sub>-C<sub>5</sub> alkyl or (CH<sub>2</sub>)<sub>n</sub>-C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

R<sup>2</sup> and R<sup>3</sup> are each independently: C<sub>1</sub>-C<sub>3</sub> alkyl;


R<sup>10</sup> is: halo, haloalkyl or C<sub>1</sub>-C<sub>3</sub> alkyl, and

wherein R<sup>10</sup> being substituted at a position 5, or 6, or both 5 and 6 of benzothiophenyl ring; and

R<sup>11</sup> is: hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl.

20. (Original) The compound of Claim 19, wherein R<sup>10</sup> is Cl, F, Br, CH<sub>3</sub> or CF<sub>3</sub> being substituted at a position 5 of benzothiophenyl ring.

21. (Original) A compound having a structural Formula IX,



and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

E is: O, S or NR<sup>14</sup>;



W is: , hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, (CH<sub>2</sub>)<sub>n</sub>-C<sub>3</sub>-C<sub>6</sub> cycloalkyl, haloalkyl or acyl;

Q is: -C(O)OR<sup>6</sup> or R<sup>6A</sup>;

X is: a bond, C, O, S or S[O]<sub>p</sub>;

Y is: a bond, S, C or O;

- Z is:
- a) aliphatic group,
  - b) aryl,
  - c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
  - d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,
  - e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and
  - f) heterocyclyl;

wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being optionally substituted with one or more groups independently selected from R<sup>15</sup>;

m and n' are each independently: 0, 1, 2, 3 or 4;

n is: 0, 1, 2 or 3;

p is: 1 or 2;

r is: 1, 2, 3 or 4;

v is: 1 or 2;

R<sup>1</sup> is: hydrogen,  
haloalkyl,  
C<sub>1</sub>-C<sub>6</sub> alkyl,  
C<sub>1</sub>-C<sub>6</sub> alkyl-C<sub>1</sub>-C<sub>6</sub> alkoxy,  
C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,  
C<sub>2</sub>-C<sub>6</sub> alkenyl,

C<sub>2</sub>-C<sub>6</sub> alkynyl,  
(CH<sub>2</sub>)<sub>n</sub> C<sub>3</sub>-C<sub>6</sub> cycloalkyl,  
C<sub>1</sub>-C<sub>6</sub> alkoxy,  
aryl, or  
R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and  
wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted  
with one or more groups independently selected from R<sup>15</sup>;

R<sup>1a</sup> and R<sup>1b</sup> are each independently:

hydrogen,  
C<sub>1</sub>-C<sub>6</sub> alkyl, or  
R<sup>1</sup> and R<sup>1a</sup>, R<sup>1</sup> and R<sup>1b</sup>, R<sup>2</sup> and R<sup>1a</sup>, R<sup>2</sup> and R<sup>1b</sup> or R<sup>1a</sup> and R<sup>1b</sup> together being a 3- to 6-  
membered heterocyclyl or carbocyclyl ring where at least one of R<sup>1a</sup> and R<sup>1b</sup> is not  
hydrogen;

R<sup>2</sup> is: hydrogen,

haloalkyl,  
C<sub>1</sub>-C<sub>6</sub> alkyl,  
C<sub>1</sub>-C<sub>6</sub> alkyl-C<sub>1</sub>-C<sub>6</sub> alkoxy,  
C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,  
C<sub>2</sub>-C<sub>6</sub> alkenyl,  
C<sub>2</sub>-C<sub>6</sub> alkynyl,  
(CH<sub>2</sub>)<sub>n</sub> C<sub>3</sub>-C<sub>6</sub> cycloalkyl,  
C<sub>1</sub>-C<sub>6</sub> alkoxy,  
aryl, or  
R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and  
wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted  
with one or more groups independently selected from R<sup>15</sup>;

R<sup>2a</sup> is: hydrogen, halo or C<sub>1</sub>-C<sub>6</sub> alkyl and wherein R<sup>2</sup> and R<sup>2a</sup> together being a 3- to 8-membered  
ring; and wherein alkyl being optionally substituted with one or more groups  
independently selected from R<sup>15</sup>;



R<sup>3</sup> is: hydrogen,  
halo,  
cyano,  
haloalkyl,  
C<sub>1</sub>-C<sub>6</sub> alkyl,  
(CH<sub>2</sub>)<sub>n</sub> C<sub>3</sub>-C<sub>6</sub> cycloalkyl,  
(C<sub>1</sub>-C<sub>4</sub> alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted with  
oxo,  
(C<sub>1</sub>-C<sub>4</sub> alkyl)-NR<sup>7</sup>C(O)<sub>p</sub>R<sup>9</sup>, and  
wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more  
groups independently selected from R<sup>15</sup>;

R<sup>4</sup> and R<sup>5</sup> are each independently:

hydrogen,  
halo,  
C<sub>1</sub>-C<sub>6</sub> alkyl  
C<sub>1</sub>-C<sub>6</sub> alkoxy;  
aryloxy;  
N(R<sup>8</sup>)<sub>2</sub>,  
SR<sup>8</sup> or  
R<sup>4</sup> and R<sup>5</sup> together being a 3- to 8-membered ring;

R<sup>6</sup> is: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or aminoalkyl;

R<sup>6A</sup> is: carboxamide, C<sub>1</sub>-C<sub>3</sub> alkyl nitrile, sulfonamide, acylsulfonamide or tetrazole;

R<sup>7</sup> is: hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>8</sup> and R<sup>9</sup> are each independently:


hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, aryl, heteroaryl, or heterocyclyl, and  
wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more  
substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo,  
haloalkyl, haloalkyloxy, aryloxy, oxo, C<sub>1</sub>-C<sub>6</sub> alkyl and C<sub>1</sub>-C<sub>6</sub> alkoxy;

$R^{14}$  is: hydrogen, aryl,  $C_1$ - $C_6$  alkyl, or  $C_1$ - $C_6$  alkyl-COOR<sup>6</sup>, and

wherein aryl and alkyl being optionally substituted with one or more groups independently selected from  $R^{15}$ ; and

$R^{15}$  is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $(CH_2)_n$ - $C_3$ - $C_6$  cycloalkyl,  $N(R^8)_2$ ,  $NR^8S(O)_2R^9$ ,  $NR^8C(O)_pR^9$ ,  $C(O)NR^8R^9$ ,  $C(O)_pR^8$ ,  $SR^8$ ,  $S(O)_pR^8$  or  $S(O)_2NR^8R^9$ .

22. (Original) The compound of Claim 21, wherein the compound having a structural Formula X:



and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

$n$  and  $q$  are each independently: 1, 2, 3 or 4;

$T$  is: O,  $NR^{10}$  or S;

$X$  is: C, O or S;

$R^1$  is: hydrogen,  $C_1$ - $C_6$  alkyl or  $(CH_2)_n$ - $C_3$ - $C_6$  cycloalkyl;


$R^{1a}$ ,  $R^{1b}$ ,  $R^{10}$  and  $R^2$  are each independently: hydrogen or  $C_1$ - $C_6$  alkyl; and

$R^{10}$  and  $R^{11}$  are each independently:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy,

$C_1$ - $C_6$  alkyl or  $C_1$ - $C_6$  alkoxy; and wherein alkyl, alkoxy and aryloxy being optionally substituted with one or more groups selected from  $R^{15}$ .

23. (Original) The compound of Claim 22, wherein the compound having a structural Formula XI:



XI

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is 1 or 2;

E is O, S or NR<sup>14</sup>;




R<sup>1</sup>, R<sup>2</sup> and R<sup>11</sup> are each independently: C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>10</sup> is: Cl, F, Br, CH<sub>3</sub> or CF<sub>3</sub>, and wherein R<sup>10</sup> being substituted at a position 5, or 6, or both 5 and 6 of benzothiophenyl ring; and

R<sup>14</sup> is: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or aryl.

24. (Original) A compound selected from the group consisting of No. 1-120 and 121:

No.	Structure	Name
1		3-(4-{2-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenyl)-propionic acid
2		3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenyl)-propionic acid
3		(4-{2-[(5-Chloro-3-methyl-benzofuran-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenoxy)-acetic acid

No.	Structure	Name
4		(4-{2-[(5-Chloro-3-methyl-benzofuran-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
5		3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenyl)-propionic acid
6		(4-{2-[(5-Chloro-3-ethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid








7		4-{2-[(6-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
8		4-{2-[(7-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
9		(4-{2-[(4-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
10		(4-{2-[(5-Chloro-3-trifluoromethylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
11		(4-{2-[(5-Chloro-3-trifluoromethylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenoxy)-acetic acid
12		2-[4-(3-{[5-(4-Fluorobiphenyl-4-yl)-thiophene-2-sulfonyl]-propyl-amino}-propyl)-phenoxy]-2-methyl-propionic acid
13		2-(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethyl}-phenoxy)-2-methyl-propionic acid







14		2-(4-{3-[(3,5-Dimethylbenzo[b]thiophene-2-sulfonyl)-propyl]-amino}-propyl)-phenoxy)-2-methyl-propionic acid
15		2-(4-{3-[(5-Fluoro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl]-amino}-propyl)-phenoxy)-2-methyl-propionic acid
16		2-(4-{3-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-(2,2,2-trifluoro-ethyl)-amino]-propyl}-phenoxy)-2-methyl-propionic acid
17		2-(4-{2-[(3-Ethylbenzo[b]thiophene-2-sulfonyl)-propyl]-amino}-ethoxy)-3-propyl-phenoxy)-2-methyl-propionic acid
18		2-[4-(1-{[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl]-amino}-methyl)-propoxy)-2-methyl-phenoxy]-2-methyl-propionic acid
19		3-[4-(1-{[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl]-amino}-methyl)-propoxy)-2-methyl-phenyl]-propionic acid

20		[4-(1-{{[(5-Fluoro-3-methylbenzo[b]thiophene-2-sulfonyl)-propylamino]-methyl]-propylsulfanyl)-2-methyl-phenoxy]-acetic acid
21		[4-(1-{{[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propylamino]-methyl]-propylsulfanyl)-2-methyl-phenoxy]-acetic acid
22		[4-(1-{{[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propylamino]-methyl]-propylsulfanyl)-2-methyl-phenoxy]-acetic acid
23		(2-Methyl-4-{2-[(6-phenoxy-pyridine-3-sulfonyl)-propylamino]-ethylsulfanyl}phenoxy)-acetic acid
24		(2-Methyl-4-{2-[(5-methyl-1-phenyl-1H-pyrazole-4-sulfonyl)-propylamino]-ethylsulfanyl}phenoxy)-acetic acid
25		(2-Methyl-4-{2-[(4-oxazol-5-yl-benzenesulfonyl)-propylamino]-ethylsulfanyl}phenoxy)-acetic acid
26		(2-Methyl-4-{2-[propyl-(4-pyrazol-1-yl-benzenesulfonyl)-amino]-ethylsulfanyl}phenoxy)-acetic acid

27		(2-Methyl-4-{2-[(2-naphthalen-1-yl-ethanesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
28		(2-Methyl-4-{2-[propyl-(4-trifluoromethylphenyl)ethanesulfonyl]-amino]-ethylsulfanyl}-phenoxy)-acetic acid
29		(4-{2-[(Biphenyl-3-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
30		(4-{2-[(2,3-Dihydrobenzo[1,4]dioxine-6-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
31		[2-Methyl-4-(2-{[5-(2-methylsulfanyl)pyrimidin-4-yl]-thiophene-2-sulfonyl}-propyl-amino)-ethylsulfanyl]-phenoxy]-acetic acid
32		[2-Methyl-4-(2-{[5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-sulfonyl]-propyl-amino)-ethylsulfanyl]-phenoxy]-acetic acid
33		[2-Methyl-4-(2-{[5-(1-methyl-3-trifluoromethyl-1H-pyrazol-4-yl)-thiophene-2-sulfonyl]-propyl-amino)-ethylsulfanyl]-phenoxy]-acetic acid
34		(R)-(2-Methyl-4-{1-methyl-2-[(3-methyl-5-trifluoromethylbenzo[b]thiophene-2-sulfonyl)-propyl-










		amino]-ethylsulfanyl)-phenoxy)-acetic acid
35		(R)-3-(4-{2-[(6-Chloro-5-fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenyl)-propionic acid
36		(R)-4-{2-[(6-Chloro-5-fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
37		(4-{2-[(4-Bromobenzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
38		(4-{2-[(3,4-Dichlorobenzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
39		(4-{2-[(4-Isopropylbenzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
40		(2-Methyl-4-{2-[(4-pentylbenzenesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
41		(4-{2-[(2-Chloro-4-trifluoromethylbenzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

42		(2-Methyl-4-{2-[(propyl-(3-trifluoromethyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl)-phenoxy}-acetic acid
43		(4-{2-[(4-Bromo-2-methyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
44		(4-{2-[(3,4-Dibromo-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
45		(2-Methyl-4-{2-[(propyl-(4-propyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl)-phenoxy}-acetic acid
46		(4-{2-[(2,4-Dichloro-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
47		(4-{2-[(4-Iodo-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

48		(4-{2-[(3-Chloro-4-methyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
49		(4-{2-[(4-Bromo-2,5-difluoro-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
50		(2-Methyl-4-{1-methyl-2-[propyl-(4-trifluoromethyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
51		(4-{2-[(3,4-Dichloro-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
52		(2-Methyl-4-{2-[propyl-(2'-trifluoromethyl-biphenyl-4-sulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
53		(2-Methyl-4-{2-[propyl-(3'-trifluoromethyl-biphenyl-4-sulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
54		(2-Methyl-4-{2-[propyl-(4'-trifluoromethyl-biphenyl-4-sulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
55		(4-{2-[(2'-Fluoro-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

56		(4-{2-[(4'-Fluorobiphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
57		(2-Methyl-4-{2-[propyl-(4'-trifluoromethoxybiphenyl-4-sulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
58		(4-{2-[(3',4'-Dichlorobiphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
59		(4-{2-[(3'-Fluorobiphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
60		(4-{2-[(2'-Chlorobiphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
61		(4-{2-[(4'-Methoxybiphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
62		(4-{2-[(4'-Methoxybiphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
63		(4-{2-[(3'-Chloro-4'-fluorobiphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

64		(4-{2-[(4-Chloro-3-trifluoromethyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
65		(2-Methyl-4-{1-methyl-2-[propyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
66		(2-Methyl-4-{1-methyl-2-[propyl-(4-propyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
67		(4-{2-[(4-Chloro-3-trifluoromethyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
68		(4-{2-[(3-Chloro-4-trifluoromethyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
69		(4-{2-[(4-Butyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
70		(4-{2-[(4-Isobutyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
71		(4-{2-[(2-Chloro-4-trifluoromethyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-phenoxy)-acetic acid

		2-methyl-phenoxy)-acetic acid
72		(4-{2-[(4-Bromo-3-chloro-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
73		(4-{2-[(4-Butyl-3-chloro-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
74		(4-{2-[(3-Chloro-4-isobutyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
75		(4-{2-[(4-Bromo-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
76		(4-{2-[(4-Butyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
77		(4-{2-[(2-Chloro-4'-fluoro-biphenyl-4-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
78		(4-{2-[(3-Chloro-4-propyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

79		(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propylamino]-ethylsulfanyl}-2-propyl-phenoxy)-acetic acid
80		(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propylamino]-ethylsulfanyl}-phenoxy)-acetic acid
81		(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propylamino]-ethylsulfanyl}-2-trifluoromethyl-phenoxy)-acetic acid
82		[2-Methyl-4-(1-[(4-trifluoromethoxybenzenesulfonyl)-amino]-methyl)-propylsulfanyl]-phenoxy]-acetic acid
83		(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propylamino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
84		(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propylamino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
85		(2-Methyl-4-{2-[(3-methyl-5-trifluoromethylbenzo[b]thiophene-2-sulfonyl)-propylamino]-ethylsulfanyl}-phenoxy)-acetic acid

86		(2-Methyl-4-{2-[(propyl-(4-trifluoromethyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
87		(4-{2-[(4-Ethyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
88		(2-Methyl-4-{2-[(2-methyl-4-trifluoromethoxy-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
89		(2-Methyl-4-{2-[(propyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
90		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
91		(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-(3-methyl-butyl)-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid








92		(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-cyclopropyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
93		(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-cyclobutyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
94		(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-cyclopropylmethyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
95		(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-pentyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
96		(4-{2-[Butyl-(5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
97		(4-{2-[(Biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
98		(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethoxy}-2-methyl-phenylsulfanyl)-acetic acid

		acetic acid
99		(4-{3-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-propyl}-2-methylphenoxy)-acetic acid
100		(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methylethoxy}-2-methylphenoxy)-acetic acid
101		3-(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methylethoxy}-2-methylphenyl)-propionic acid
102		2-(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methylethoxy}-2-methylphenoxy)-2-methylpropionic acid
103		3-(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methylethoxy}-2-methoxyphenyl)-propionic acid
104		(4-{2-[(5-Fluoro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methylethylsulfanyl}-2-methylphenoxy)-acetic acid

105		3-(4-{2-[(5-Fluoro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methylethoxy}-2-methylphenyl)-propionic acid
106		(4-{2-[(5-Fluoro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methylethoxy}-2-methylphenoxy)-acetic acid
107		(2-Chloro-4-{2-[(5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
108		(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-ethylphenoxy)-acetic acid
109		(2-Methyl-4-{2-[(naphthalene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
110		(4-{2-[(5-Fluoro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methylphenoxy)-acetic acid

111		[3-Chloro-4-(1-[[propyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]-methyl]-propylsulfanyl)-phenyl]-acetic acid
112		(R)-(3-Chloro-4-[2-[[[(5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl]-phenyl]-acetic acid
113		(3-Chloro-4-[2-[[[(5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl]-phenyl]-acetic acid
114		[4-(1-[[[(5-Fluoro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl]-propoxy]-2-methylphenoxy]-acetic acid
115		3-[4-(1-[[[(5-Fluoro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl]-propoxy]-2-methylphenyl]-propionic acid
116		3-(4-[2-[[[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-butoxy]-2-methyl-phenyl]-propionic acid

117		[4-(1-{[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propylamino]-methyl}-propoxy)-2-methylphenoxy]-acetic acid
118		[4-(1-{[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propylamino]-methyl}-propoxy)-2-methoxyphenoxy]-acetic acid
119		(4-{2-[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-phenethylamino]-ethylsulfanyl}-2-methylphenoxy)-acetic acid
120		(4-{2-[Benzyl-(5-chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-amino]-ethylsulfanyl}-2-methylphenoxy)-acetic acid
121		[4-(1-{[(5-Chloro-3-methylbenzo[b]thiophene-2-sulfonyl)-propylamino]-methyl}-propylsulfanyl)-2-methylphenoxy]-acetic acid

25. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound of Claim 1 or pharmaceutically acceptable salts, solvates or hydrates thereof.

26. (Cancelled)

27. (Cancelled)

- 28. (Cancelled)
- 29. (Cancelled)
- 30. (Cancelled)
- 31. (Cancelled)
- 32. (Cancelled)
- 33. (Cancelled)
- 34. (Previously Presented) A method for lowering blood-glucose in a mammal comprising the step of administering an effective amount of at least one compound of Claim 1.
- 35. (Cancelled)
- 36. (Cancelled)
- 37. (Cancelled)
- 38. (Cancelled)
- 39. (Cancelled)
- 40. (Cancelled)